Clinical Trial Detail

NCT ID NCT04216472
Title Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Alpelisib + Nab-paclitaxel

Age Groups: senior adult

Additional content available in CKB BOOST